BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have received an average rating of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $253.69.

Several brokerages have recently commented on BGNE. JMP Securities initiated coverage on shares of BeiGene in a research report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective for the company. TD Cowen lifted their price target on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Morgan Stanley reissued an “overweight” rating and set a $300.00 price objective on shares of BeiGene in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. boosted their price objective on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a report on Tuesday, October 22nd. Finally, StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st.

Insiders Place Their Bets

In other BeiGene news, insider Lai Wang sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $220.35, for a total value of $1,101,750.00. Following the completion of the sale, the insider now owns 920,920 shares of the company’s stock, valued at $202,924,722. This represents a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Xiaodong Wang sold 41,760 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $186.90, for a total transaction of $7,804,944.00. The disclosure for this sale can be found here. Insiders have sold 1,131,622 shares of company stock worth $212,520,787 in the last three months. 7.43% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Raymond James & Associates boosted its position in BeiGene by 0.4% during the 2nd quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock valued at $3,035,000 after buying an additional 76 shares during the period. Van ECK Associates Corp lifted its stake in shares of BeiGene by 8.9% in the second quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock worth $13,636,000 after buying an additional 7,816 shares in the last quarter. Fiera Capital Corp boosted its stake in BeiGene by 45.9% during the 2nd quarter. Fiera Capital Corp now owns 3,736 shares of the company’s stock valued at $533,000 after purchasing an additional 1,176 shares during the last quarter. TD Asset Management Inc boosted its position in shares of BeiGene by 1.4% during the second quarter. TD Asset Management Inc now owns 114,378 shares of the company’s stock valued at $16,318,000 after buying an additional 1,599 shares during the last quarter. Finally, Headlands Technologies LLC boosted its holdings in shares of BeiGene by 761.2% during the 2nd quarter. Headlands Technologies LLC now owns 2,773 shares of the company’s stock valued at $396,000 after acquiring an additional 2,451 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Price Performance

BGNE stock opened at $181.62 on Wednesday. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The firm has a market cap of $17.71 billion, a price-to-earnings ratio of -22.04 and a beta of 0.57. The company’s fifty day simple moving average is $200.00 and its 200 day simple moving average is $188.12. BeiGene has a 12-month low of $126.97 and a 12-month high of $248.16.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.26 million. During the same period in the prior year, the firm earned $2.01 earnings per share. The firm’s revenue for the quarter was up 28.2% compared to the same quarter last year. On average, analysts expect that BeiGene will post -5.64 earnings per share for the current year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.